Retatrutide: Research Overview

Retatrutide (LY3437943) is an investigational triple agonist peptide that targets three incretin and metabolic hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple receptor engagement strategy — sometimes described as a “triagonist” approach — represents the next step in incretin-based metabolic research beyond dual GIP/GLP-1 agonists like Tirzepatide. The inclusion of glucagon receptor agonism is of particular interest to researchers studying energy expenditure and hepatic glucose metabolism, as glucagon plays a distinct role in promoting fat oxidation and thermogenesis.

Mechanism of Action

Retatrutide combines the insulin-stimulating and appetite-suppressing effects of GLP-1 receptor activation, the beta cell and adipose tissue effects of GIP receptor activation, and the energy expenditure and gluconeogenesis-promoting effects of glucagon receptor agonism. The glucagon component is of research interest because it appears to amplify metabolic rate and promote hepatic fat mobilization, while the GLP-1 component simultaneously counteracts the hyperglycemic potential of glucagon — resulting in net glycemic neutrality or improvement. This mechanistic interplay has generated considerable research interest in how triple receptor engagement compares to dual and single agonist approaches.

Key Research Areas

• Advanced Obesity Research: Preclinical studies have documented substantial reductions in body weight and adipose tissue mass in diet-induced obesity models, with data suggesting greater efficacy than dual GIP/GLP-1 agonists.
• Hepatic Metabolism and NAFLD Models: The glucagon component has prompted investigation in non-alcoholic fatty liver disease models, where hepatic lipid mobilization and glucose output are key endpoints.
• Energy Expenditure Research: Glucagon receptor activation’s role in thermogenesis and metabolic rate has been studied alongside GLP-1 and GIP effects, with Retatrutide as a model compound.
• Glycemic Control in Diabetes Models: Research has examined whether the glucagon component disrupts the glycemic benefits of GLP-1/GIP activation or whether the net effect remains favorable for blood glucose regulation.

Research Applications

Retatrutide is used in metabolic disease research, obesity biology, and incretin pharmacology. It is particularly valuable in studies where researchers want to examine the contribution of glucagon receptor agonism to metabolic outcomes in the context of combined GIP and GLP-1 activation. Animal models of obesity and type 2 diabetes are the primary in vivo contexts, with subcutaneous administration protocols. In vitro applications include pancreatic and hepatic cell lines where receptor signaling crosstalk can be characterized.

Storage and Handling

Retatrutide is supplied as a lyophilized powder for research use. Store at -20°C in a dry, light-protected environment. Reconstitute with sterile bacteriostatic water using aseptic technique. Once reconstituted, store at 2–8°C and use within 28 days. Avoid freeze-thaw cycles after reconstitution to preserve peptide integrity.

Available from Alpha Peptides US

Alpha Peptides US offers Retatrutide 10mg for qualified laboratory research. Suitable for triple incretin receptor studies and advanced metabolic research models.

This product is intended for laboratory research purposes only. It is not approved by the FDA and is not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.